HK1072259A1 - Indole derivatives useful as histamine h3 antagonists - Google Patents

Indole derivatives useful as histamine h3 antagonists

Info

Publication number
HK1072259A1
HK1072259A1 HK05105092A HK05105092A HK1072259A1 HK 1072259 A1 HK1072259 A1 HK 1072259A1 HK 05105092 A HK05105092 A HK 05105092A HK 05105092 A HK05105092 A HK 05105092A HK 1072259 A1 HK1072259 A1 HK 1072259A1
Authority
HK
Hong Kong
Prior art keywords
histamine
antagonists
indole derivatives
derivatives useful
useful
Prior art date
Application number
HK05105092A
Other languages
English (en)
Inventor
Robert G Aslanian
Michael Y Berlin
Pietro Mangiaracina
Cormick Kevin D Mc
Mwangi W Mutahi
Stuart B Rosenblum
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1072259A1 publication Critical patent/HK1072259A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
HK05105092A 2002-06-24 2005-06-18 Indole derivatives useful as histamine h3 antagonists HK1072259A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39098702P 2002-06-24 2002-06-24
PCT/US2003/019619 WO2004000831A1 (en) 2002-06-24 2003-06-20 Indole derivatives useful as histamine h3 antagonists

Publications (1)

Publication Number Publication Date
HK1072259A1 true HK1072259A1 (en) 2005-08-19

Family

ID=30000654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105092A HK1072259A1 (en) 2002-06-24 2005-06-18 Indole derivatives useful as histamine h3 antagonists

Country Status (22)

Country Link
US (1) US6951871B2 (es)
EP (2) EP1539742B1 (es)
JP (1) JP4326468B2 (es)
KR (1) KR20050009757A (es)
CN (1) CN100497334C (es)
AR (1) AR039718A1 (es)
AT (1) ATE344798T1 (es)
AU (1) AU2003243709B2 (es)
CA (1) CA2489337C (es)
CY (1) CY1105986T1 (es)
DE (1) DE60309598T2 (es)
DK (1) DK1539742T3 (es)
ES (1) ES2271644T3 (es)
HK (1) HK1072259A1 (es)
IL (1) IL165863A0 (es)
MX (1) MXPA05000193A (es)
MY (1) MY135686A (es)
NZ (1) NZ537200A (es)
PT (1) PT1539742E (es)
TW (1) TW200400031A (es)
WO (1) WO2004000831A1 (es)
ZA (1) ZA200410213B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2491079C (en) * 2002-06-28 2011-10-04 Donald J. Kyle Therapeutic piperazine derivatives useful for treating pain
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
CA2569611C (en) * 2004-06-21 2012-12-11 F. Hoffmann-La Roche Ag Indole derivatives as histamine receptor antagonists
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
KR20070100277A (ko) * 2004-12-06 2007-10-10 아벤티스 파마 소시에떼아노님 치환된 인돌, 그를 함유하는 조성물, 그의 제조 방법 및그의 용도
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2006207712A1 (en) 2005-01-19 2006-07-27 F. Hoffmann-La Roche Ag 5-aminoindole derivatives
WO2007001975A1 (en) 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1931665A1 (en) * 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
EP1966199B1 (en) * 2005-11-18 2010-10-20 F. Hoffmann-La Roche AG Azaindole-2-carboxamide derivatives
AU2006319235A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2007075629A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
PE20071136A1 (es) * 2005-12-21 2007-12-29 Schering Corp Derivados de anilina sustituida como antagonistas de la histamina h3
JP2010519171A (ja) * 2006-02-17 2010-06-03 メモリー・ファーマシューティカルズ・コーポレイション 5−ht6受容体親和性を有する化合物
US7514433B2 (en) * 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US8153660B2 (en) * 2006-10-27 2012-04-10 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol CCR3 modulators
EP2079731B1 (en) * 2006-10-27 2011-09-14 Boehringer Ingelheim International GmbH Novel substituted piperidyl-propane-thiols
KR20100053626A (ko) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 5-ht6 수용체 친화성을 나타내는 3'-치환된 화합물
CA2956278C (en) * 2008-01-04 2022-03-01 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine and applications thereof
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2318387A1 (en) * 2008-07-23 2011-05-11 Schering Corporation Bicyclic heterocycle derivatives as histamine h3 receptor antagonists
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
EP2556068B1 (en) 2010-04-08 2019-01-23 Respivert Limited P38 map kinase inhibitors
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑
EP3797769A1 (fr) 2019-09-25 2021-03-31 Fontès, M. Michel Composition a usage therapeutique
CN116194102A (zh) 2020-07-15 2023-05-30 沙巴研究联合有限责任公司 用于治疗急性疼痛和降低胃灼热的严重程度和/或风险的包含布洛芬和法莫替丁的单位口服剂量组合物
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730037B2 (ja) 1987-03-13 1995-04-05 第一製薬株式会社 ピリミジニルプロピオン酸誘導体
DK181190D0 (da) 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
WO1998006394A1 (en) 1996-08-16 1998-02-19 Schering Corporation Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
SK68399A3 (en) * 1996-11-25 2000-07-11 Procter & Gamble 2-imidazolinylaminoindole compound, pharmaceutical composition containing the same and use thereof
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2001046181A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Indole derivatives for the treatment of depression and anxiety
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
JP2004529117A (ja) * 2001-02-08 2004-09-24 シェーリング コーポレイション 認知欠陥障害の処置における二重のh3/m2アンタゴニストの使用
JP4522651B2 (ja) 2001-03-13 2010-08-11 シェーリング コーポレイション 新規非イミダゾール化合物

Also Published As

Publication number Publication date
MY135686A (en) 2008-06-30
DK1539742T3 (da) 2006-12-27
AU2003243709B2 (en) 2007-01-18
CN100497334C (zh) 2009-06-10
CA2489337C (en) 2010-05-25
TW200400031A (en) 2004-01-01
ATE344798T1 (de) 2006-11-15
JP4326468B2 (ja) 2009-09-09
CN1662524A (zh) 2005-08-31
US6951871B2 (en) 2005-10-04
AU2003243709A1 (en) 2004-01-06
NZ537200A (en) 2007-09-28
KR20050009757A (ko) 2005-01-25
CY1105986T1 (el) 2011-04-06
EP1539742A1 (en) 2005-06-15
MXPA05000193A (es) 2005-04-08
DE60309598T2 (de) 2007-09-13
WO2004000831A1 (en) 2003-12-31
DE60309598D1 (de) 2006-12-21
ZA200410213B (en) 2005-10-20
IL165863A0 (en) 2006-01-15
EP1777223A1 (en) 2007-04-25
JP2005531615A (ja) 2005-10-20
US20040019099A1 (en) 2004-01-29
AR039718A1 (es) 2005-03-09
PT1539742E (pt) 2007-01-31
EP1539742B1 (en) 2006-11-08
CA2489337A1 (en) 2003-12-31
ES2271644T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
HK1072259A1 (en) Indole derivatives useful as histamine h3 antagonists
PL373889A1 (en) (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
IL163892A0 (en) Indolylmaleimide derivatives
IL165810A0 (en) Novel benzimidazole derivatives
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
IL179737A0 (en) Indole derivatives as histamine receptor antagonists
PL377087A1 (pl) Związki heterocykliczne
PL375111A1 (en) Novel substituted indoles
SI1487805T1 (sl) Pirimidinski derivati
HK1093070A1 (en) Imidazole derivatives as glutamate receptor antagonists
PL372295A1 (en) Quinoline derivatives as npy antagonists
GB0315870D0 (en) Heterocyclic derivatives
IL166404A0 (en) Indoline derivatives substituted in
PL377609A1 (pl) Pochodne indazolu jako antagoniści CRF
HK1093071A1 (en) Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists
PL372463A1 (en) Thiazole derivatives as npy receptor antagonists
EP1476425A4 (en) Heterocyclic Aryl Sulphonamidocyclic Compounds
AU2003280838A8 (en) Indole derivatives as somatostatin agonists or antagonists
AU2002356369A1 (en) Xanthine derivatives as muscarinic receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2003297408A1 (en) Thiazole compounds as integrin receptor antagonists derivatives
SI1539742T1 (sl) Indolni derivati, uporabni kot antagonisti histamina H3
GB0220962D0 (en) Heterocyclic derivatives
GB0220961D0 (en) Heterocyclic derivatives
GB0209990D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110620